Is Amgen a healthcare stock worth considering? [Video]

Giles Coghlan LLB, Lth, MA Financial Source

Amgen is a multinational biopharmaceutical company that specializes in the development and manufacturing of innovative therapies to treat serious illnesses. The company is focused on using advanced biotechnology and scientific research to address some of the most complex medical conditions, including cancer, cardiovascular disease, kidney disease, inflammatory diseases, and bone disorders.

As a healthcare stock, the company can potentially weather any tougher US financial conditions that may be ahead. This is because even during a recession, healthcare needs are still prioritized, supporting healthcare stocks.

Over the last 20 years, Amgen’s share price has risen 85% of the time between May 31 and July 29, with an average return of 9.14% and an annualized return of over 72%. So, in the face of worries over a looming US recession, is Amgen a healthcare stock worth considering?

Major trade risks: The biggest risk here is if Congress fails to pass the US debt ceiling talks in a timely manner. This could potentially send US stocks into a freefall.

Learn more about HYCM

Author

Giles Coghlan LLB, Lth, MA

Financial Source

Giles is the chief market analyst for Financial Source. His goal is to help you find simple, high-conviction fundamental trade opportunities. He has regular media presentations being featured in National and International Press.

EUR/USD hovers above 1.1800 as USD stabilizes

EUR/USD treads water above 1.1800 in the European session on Thursday. The US Dollar stabilizes, following the recent decline fuelled by concerns about the economic fallout from US President Trump's erratic trade policies, capping the pair's upside. All eyes now remain on Lagarde's speech and US-Iran nuclear talks.

GBP/USD extends recovery to near 20-day EMA as US Dollar weakens

The Pound Sterling holds onto weekly gains around 1.3565 against the US Dollar during the Asian trading session on Thursday. The GBP/USD pair trades firmly as the US Dollar remains under pressure due to uncertainty surrounding the United States trade policy outlook.

Gold clings to gains amid sustained safe-haven flows ahead of US-Iran talks

Gold sticks to its modest intraday gains through the first half of the European session on Thursday, with bulls still awaiting a sustained move and acceptance above the $5,200 mark before placing fresh bets.

Stellar: Relief bounce fades as bearish undertone persists

Stellar is trading around $0.16 at the time of writing on Thursday after rebounding more than 8% in the previous day. Derivatives data paints a negative picture as XLM’s short bets hit a monthly high while Open Interest continues to decline.

Nvidia delivers another monster earnings report, and forecasts big things to come

It was another monster earnings report from Nvidia for fiscal Q4. Revenues were $68.1bn, smashing estimates of $65bn. Gross profit margin was a healthy 75%, up from 73.5% in the prior quarter, and the outlook for this quarter was monstrous.

Solana strikes key resistance with double-digit gains

Solana trades at $88 at press time on Thursday, after an 11% upswing the previous day within a broader consolidation range of roughly three weeks. Institutional demand for Solana heightens as US spot SOL Exchange Traded Funds record $30 million of inflow on Wednesday.